← Previous Post: | Next Post:


“Sidney Zisook [of the University of California San Diego], the key committee adviser who developed the scientific report justifying the change on bereavement, has had close [drug industry] ties …. He has served as a speaker for AstraZeneca and Forest and as a consultant to Glaxo, though that work preceded his work for the committee by at least two years, he said. He was also the lead author of the Glaxo study showing that Wellbutrin can be used to treat the bereaved.”

When the evidence – often ambiguous and often paid for by drug-makers – allows you to go pretty much anywhere, you’ll go where the money is.

Actually, the evidence about whether people grieving the loss of someone they loved are more susceptible to clinical depression and suicide seems to be… no.

[In] a major national survey, none of the bereaved who now could be subject to a diagnosis of depression had attempted suicide. Other data sets … showed similar results — indeed, such individuals are less likely to attempt suicide than someone in the general population.

Indeed now people who show up for their on-average seven minute visit to their primary doctor and who are overtly sad because someone important to them recently died may be subject to a depression diagnosis and all the anti-depressant pills thereto.

It’s all there in the latest Diagnostic and Statistical Manual, the big book your doctor thumbs through to treat your grief.

Treat your grief. How’s your grief treatment going? Something new enters the language.

Margaret Soltan, December 28, 2012 10:57AM
Posted in: conflict of interest

Trackback URL for this post:

Comment on this Entry

Latest UD posts at IHE